AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Combining Systemic Therapies: Should You Do It?

Description

The discussion focuses on the approach and benefits of combining systemic medical therapies for various connective tissue diseases, particularly dermatomyositis, lupus, and scleroderma. It highlights the complex pathophysiology involved in these conditions, emphasizing the interplay of immune cells and cytokines. The session outlines strategies for combination therapies in treating these diseases, citing clinical trials that demonstrate the efficacy of adding medications like apremilast and tofacitinib to standard treatments. The trials showed improvements in patient outcomes with manageable side effects, underscoring the importance of monitoring toxicity and the potential risks associated with combination therapies. The talk also covers the use of Jack inhibitors and biological agents in treating lupus and systemic sclerosis, noting that they offer additional options for patients who do not respond adequately to first-line therapies. Ultimately, the speaker encourages clinicians to utilize a layered approach to treatment, combining traditional and newer agents to improve patient quality of life, while counseling patients on the risks and benefits of such strategies.

View more

Conclusions

  • Combination therapy is essential for effectively managing connective tissue diseases due to their complex pathophysiology.
  • The addition of apremilast to existing therapies showed potential for improving symptoms in resistant cases of dermatomyositis without significant side effects.
  • JAK inhibitors, such as tofacitinib and baricitinib, are emerging as promising add-on therapies that can enhance response in hard-to-treat dermatomyositis patients.
  • There is a notable increase in safety and efficacy when combining systemic therapies in lupus management, particularly with newer biologics and targeted therapies.
  • Combining older immunosuppressive agents with newer therapies may improve patient outcomes and quality of life.
  • Monitoring for side effects is crucial when applying combination therapies, especially to manage the risk of infections.
  • Combination treatment strategies must be personalized based on disease severity, patient response, and existing comorbidities to optimize therapeutic outcomes.
  • Wahren-Herlenius, M., & Dörner, T. (2013). Immunopathogenic mechanisms of systemic autoimmune disease. The Lancet, 382(9894), 819-831.
  • Waldman, R. et al. (2020). Dermatomyositis: Diagnosis and treatment. Journal of the American Academy of Dermatology, February 2020.
  • Bitar, C. et al. (2022). Apremilast in Recalcitrant Cutaneous Dermatomyositis A Nonrandomized Controlled Trial. JAMA Dermatology, 158(12), 1357-1366.
  • Plante, M. et al. (2022). A Retrospective Review of Tofacitinib in the Treatment of Refractory Dermatomyositis. J Drugs Dermatol, 21(10), 1133-1134.
  • Paudyal, B. et al. (2021). JAK-inhibitors for dermatomyositis: A concise literature review. Dermatology Therapy, 34(3), e14939. doi: 10.1111/dth.14939.
  • Landon-Cardinal, O. et al. (2023). JAK inhibitors for the treatment of adult dermatomyositis: A pilot study. Journal of the American Academy of Dermatology, 88(4), 924-926.
  • Shaw, M. et al. (2023). Rapid Improvement in Recalcitrant Cutaneous Juvenile Dermatomyositis With Anifrolumab Treatment. JAMA Dermatology. doi:10.1001/jamadermatol.2023.4744.
  • Fanouriakis, A. et al. (2024). EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the Rheumatic Diseases, 83, 15-29.
  • Morand, E. et al. (2023). Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis & Rheumatology, 75(2), 242-252.